Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avastin To Be Standard Add-On Agent In Colorectal Cancer, Genentech Says

Executive Summary

Genentech believes that its investigational agent Avastin will become standard add-on therapy to chemotherapy in the treatment of colorectal cancer after unveiling data demonstrating that the VEGF inhibitor "markedly" improves survival in first-line metastatic disease

You may also be interested in...



Genentech Avastin Clears FDA; Colorectal Cancer Drug Costs $4,400 A Month

Genentech is launching its oncologic Avastin at a wholesale acquisition cost of $2,200 per dose for the average colorectal cancer patient

Genentech Avastin Clears FDA; Colorectal Cancer Drug Costs $4,400 A Month

Genentech is launching its oncologic Avastin at a wholesale acquisition cost of $2,200 per dose for the average colorectal cancer patient

Gilead Leads Biotech Rebound In 2003: Product Stories Play Well

Gilead Sciences is leading a new wave of biotech stocks attempting to break out of the start-up phase to become full-fledged biopharma companies

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS041917

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel